Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle
Open Access
- 1 August 2015
- journal article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 21 (8) , 767.e1-767.e4
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- In vitro activity of MCB3681 against Clostridium difficile strainsAnaerobe, 2014
- Ecological impact of MCB3837 on the normal human microbiotaInternational Journal of Antimicrobial Agents, 2014
- Effect of new antimicrobial agents on the ecological balance of human microfloraAnaerobe, 2012
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- Animal model pharmacokinetics and pharmacodynamics: a critical reviewInternational Journal of Antimicrobial Agents, 2002
- Dicyclic and Tricyclic Diaminopyrimidine Derivatives as Potent Inhibitors of Cryptosporidium parvum Dihydrofolate Reductase: Structure-Activity and Structure-Selectivity CorrelationsAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Models, In Vivo Models, and Pharmacokinetics: What Can We Learn from In Vitro Models?Clinical Infectious Diseases, 2001
- Effect of antimicrobial agents on the ecological balance of human microfloraThe Lancet Infectious Diseases, 2001
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal modelsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990